Streetbeat News

Products Services

CHRS

Coherus announced final overall survival results of the JUPITER-02 Phase 3 trial evaluating toripalimab in nasopharyngeal carcinoma. The trial showed a statistically significant improvement in overall survival for patients treated with toripalimab combined with chemotherapy, compared to chemotherapy alone.

Portfolio Pulse from Benzinga Newsdesk

June 05, 2023 | 9:33 pm

AAPL

Apple unveiled its Vision Pro mixed reality headset at WWDC 2023, priced at $3,499 and expected to launch early next year. Wedbush's Dan Ives maintains an Outperform rating on Apple and a $205 price target, predicting increased sales for the Vision Pro despite its high price.

Portfolio Pulse from AJ Fabino

June 05, 2023 | 9:28 pm

EA

NKE

EA Sports, a division of Electronic Arts (NASDAQ:EA), and Nike Virtual Studios have announced a partnership to integrate Nike's (NYSE:NKE) .SWOOSH NFTs into upcoming EA Sports games like 'Madden 24' and 'EA Sports FC'. The collaboration aims to bring creativity and self-expression to the forefront for fans.

Portfolio Pulse from Franca Quarneti

June 05, 2023 | 9:18 pm

CMPS

MNMD

NUMIF

Numinus Wellness' Cedar Clinical Research (CCR) is a top research site for MindMed's Phase 2b study on LSD compound MM-120 for General Anxiety Disorder. CCR has enrolled and dosed 19 trial participants and is enrolling volunteers at a second research clinic. Numinus is also a site for COMPASS Pathways' clinical trial of psilocybin therapy for Treatment-Resistant Depression.

Portfolio Pulse from Lara Goldstein

June 05, 2023 | 8:27 pm

RMAX

RE/MAX has expanded its presence in the South Pacific by selling the master franchise rights in the Republic of Fiji. This move is expected to strengthen the company's global footprint.

Portfolio Pulse from Benzinga Newsdesk

June 05, 2023 | 8:20 pm

OGEN

Oragenics has been awarded a grant from CQDM for the development of a variant-agnostic protein antigen for use in its COVID-19 intranasal vaccine.

Portfolio Pulse from Benzinga Newsdesk

June 05, 2023 | 8:20 pm

BIIB

DNLI

Biogen and Denali Therapeutics are discontinuing a Phase 3 program for BIIB122, a Parkinson's disease treatment, amidst R&D restructure. The companies will now focus on the ongoing Phase 2b LUMA study in patients with early-stage Parkinson's.

Portfolio Pulse from Vandana Singh

June 05, 2023 | 8:15 pm

GM

TSLA

Tesla CEO Elon Musk has offered to collaborate with other automakers, including licensing Autopilot and Full Self-Driving technology, to accelerate EV adoption. This follows General Motors' recent acknowledgment of Tesla's leadership in the EV market.

Portfolio Pulse from Benzinga EV Insights

June 05, 2023 | 8:14 pm

DOX

Amdocs has launched amAIz, a generative AI framework designed to accelerate the development of AI applications. The framework aims to simplify AI adoption and reduce time-to-market for AI solutions.

Portfolio Pulse from Benzinga Newsdesk

June 05, 2023 | 8:09 pm

PGEN

Precigen announced Phase 1 data for PRGN-3005 UltraCAR-T cells, an overnight-manufactured treatment for advanced stage platinum-resistant ovarian cancer patients, at the 2023 ASCO Annual Meeting.

Portfolio Pulse from Benzinga Newsdesk

June 05, 2023 | 8:09 pm